FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 444 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Dr. Catherine Hamlin, Pioneer In Fistula Surgery, Passes Away At Age... March 23, 2020 Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors November 15, 2019 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Load more HOT NEWS Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... Eight Factors May Link Disparities in Cancer Death Rates and Income ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July Should CAR T Cells Be Used Earlier in People with Non-Hodgkin...
